Richard Nieman - Jan 30, 2024 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Medical Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact
Stock symbol
LYRA
Transactions as of
Jan 30, 2024
Transactions value $
$0
Form type
4
Date filed
2/1/2024, 04:15 PM
Previous filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Options Award $0 +200K $0.00 200K Jan 30, 2024 Common Stock 200K $4.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 30, 2024.